Lisata Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.02 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Details
| Name | Lisata Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 21 |
| Founded | 1980 |
| Ceo | David Mazzo |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1280583022 |
| Cusip | 128058302 |
| Cik | 0000320017 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | Chief Executive Officer and Director |
| James Nisco | SVice President of Finance and Treasury and Chief Accounting Officer |
| Dr. Joshua Lehrer-Graiwer FACC, M.D. | President and Chief Operating Officer |
Contact
| Address | 110 Allen Road, 2nd Floor, Basking Ridge, New Jersey 07920, United States |
| Phone | 908 842 0100 |
| Website | https://www.lisata.com |